Seminars and Events

Artificial Intelligence Research for Health

Optimizing Clinical Trial Design: The Role of AI in Boosting Inclusivity and Efficiency

Event Details

Abstract: Toward a new era of medicine, one mission is to revolutionize clinical trial methodologies by harnessing the power of artificial intelligence (AI). This talk explores how AI can enhance the effectiveness and inclusiveness of clinical trial designs. I will first discuss Trial Pathfinder, a computational framework to optimize clinical trial designs. Trial Pathfinder simulates synthetic patient cohorts from medical records, and enables inclusive criteria and data valuation. In the second part, I will focus on the development of a question-and-answer platform for clinical trial design using large language models (LLMs). This platform is engineered to provide comprehensive and precise information, assisting in the intricate process of clinical trial planning.

Host: Michael Pazzani, Principal Scientist

We have arranged a lunch following the talk to promote discussion, from 12 – 1:00pm.

Register for in-person attendance and lunch here.

If you would like to speak with Dr. Liu in person between 1pm and 3pm, you may sign up here 

In-person attendance is open to all USC affiliates.  This requires checking in with reception on the 10th floor, where you will be directed to conference room 1014. We will also validate parking.

Students and postdocs are welcome. There is a shuttle from UPC: Marina del Rey Shuttle – USC Transportation


Speaker Bio

Ruishan Liu is an incoming Assistant Professor of Computer Science at USC. She received her PhD at Stanford University in 2022. Her research lies in the intersection of machine learning and applications in human diseases, health and genomics. She was selected as the Rising Star in Data Science, the Next Generation in Biomedicine, and the Rising Star in Engineering in Health. She led the project Trial Pathfinder - AI for clinical trials design, which was selected as Top Ten Clinical Research Achievement in 2022 and Finalist for Global Pharma Award in 2021.